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WNK lysine-deficient protein kinase 4 (WNK4) is an impor-
tant regulator of renal salt handling.Mutations in its gene cause
pseudohypoaldosteronism type II, mainly arising from overac-
tivation of the renal Na/Cl cotransporter (NCC). In addition
to full-length WNK4, we have observed faster migrating bands
(between 95 and 130 kDa) in Western blots of kidney lysates.
Therefore, we hypothesized that these could correspond to
uncharacterized WNK4 variants. Here, using several WNK4
antibodies and WNK4/ mice as controls, we showed that
these bands indeed correspond to shortWNK4 variants that are
not observed in other tissue lysates. LC-MS/MSconfirmed these
bands as WNK4 variants that lack C-terminal segments. In
HEK293 cells, truncation ofWNK4’s C terminus at several posi-
tions increased its kinase activity toward Ste20-related proline/
alanine-rich kinase (SPAK), unless the truncated segment
included the SPAK-binding site. Of note, this gain-of-function
effect was due to the loss of a protein phosphatase 1 (PP1)-bind-
ing site in WNK4. Cotransfection with PP1 resulted in WNK4
dephosphorylation, an activity that was abrogated in the PP1-
binding siteWNK4mutant. The electrophoretic mobility of the
in vivo short variants of renalWNK4suggested that they lack the
SPAK-binding site and thus may not behave as constitutively
active kinases toward SPAK. Finally, we show that at least one
of the WNK4 short variants may be produced by proteolysis
involving a Zn2-dependent metalloprotease, as recombinant
full-length WNK4 was cleaved when incubated with kidney
lysate.
WNK lysine-deficient protein kinase 4 (WNK4)3 is a serine-
threonine kinase that is present in several tissues, including
brain, lungs, liver, and heart, with the highest expression levels
observed in kidney, colon, and testes (1). Mutations occurring
within a specific motif in WNK4, the acidic motif, produce
the human genetic disease pseudohypoaldosteronism type II
(PHAII) (2). This disease features hypertension, hyperkalemia,
metabolic acidosis, andmarked sensitivity to thiazide diuretics,
alterations that are thought to be mainly due to higher basal
activity of the renal thiazide–sensitive Na/Cl cotransporter
(NCC), which is specifically expressed in the distal convoluted
tubule (DCT) of the nephron (3, 4). Decreased activity levels of
the K channel ROMK and Na channel ENaC may also con-
tribute (5). The acidic motif of WNK4 constitutes the binding
site for the cullin-RING E3 ubiquitin ligase complex formed by
cullin 3, Kelch-like 3, and an E3 ring ubiquitin ligase, which
regulates the degradation of the kinase (6, 7). Thus, PHAII
mutations occurring in thismotif decrease the degradation rate
of the kinase, leading to its overexpression.
WNK4-knockout mice present markedly decreased levels
of NCC expression and virtually no NCC phosphorylation.
Accordingly, the phenotype of WNK4-knockout mice resem-
bles that of patients with Gitelman disease, featuring hypoten-
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sion, hypokalemia, and metabolic alkalosis, which is caused by
inactivating mutations in NCC (8). Thus, WNK4 is a key regu-
lator of NCC, and its activity is essential to maintain basal NCC
activity levels.
WNK4 promotes NCC activation through the phosphoryla-
tion of the T-loop of the Ste20-related proline/alanine–rich
kinase (SPAK), which in turn phosphorylates key residues for
NCC activation located in the N-terminal, cytoplasmic domain
of the cotransporter (9, 10). In contrast, the regulatory effect of
WNK4 on ROMK and ENaC appears to be independent of
kinase activity (11, 12). Recently, it was shown that knock-in
mice carrying a constitutively active form of SPAK in the DCT
develop PHAII (3). Thus,WNK4’s direct effects on ROMK and
ENaC do not seem to be essential to develop the disease.
WNK4 kinase activity is regulated by at least two different
mechanisms. Binding of a chloride ionwithin a site located near
the active site of the kinase stabilizes an inactive conformation
and prevents kinase activity (13, 14). Thus, at high intracellular
chloride concentrations ([Cl]i), chloride ions remain bound to
these sites, inhibiting WNK4 activity. Conversely, when [Cl]i
decreases, dissociation of Cl ions allows kinase activation.
This mechanism has been shown to be important for NCC
modulation in response to changes in extracellular K concen-
tration ([K]e), because changes in [K]e affect the intracellular
Cl concentration of DCT cells (15).
The second known regulatory mechanism of WNK4 kinase
activity involves phosphorylation of at least two sites, Ser-64
and Ser-1196, located within the regulatory N- and C-terminal
domains of WNK4, respectively (16). Phosphorylation of these
sites promotes kinase activation; it can be conducted by protein
kinase C or protein kinase A, and it is stimulated, for example,
in response to AT1 receptor activation by angiotensin II. So far,
the mechanism linking phosphorylation to kinase activation
is unknown; however, both the N-terminal and C-terminal
domains of WNK4 have long been thought to play a regulatory
role (17–19), and several functional motifs have been described
in the C-terminal domain (16). For instance, the acidic domain
(2), two PF2-like domains (20), two putative PP1-binding
motifs (21), one RFXVmotif (22), and the HQmotif important
for WNK dimerization (23, 24) have been described within the
C-terminal domain of WNK4.
During our recent characterization of the WNK4-knockout
mouse strain (8), we noticed that several bands smaller than
that corresponding to the full-length WNK4 were observed in
blots of renal tissues performed with an antibody directed
against an N-terminal epitope; these were absent in samples
from the knockout animals, ruling them out as nonspecific sig-
nals. Thus, we hypothesized that these bands could correspond
to previously unrecognized variants of WNK4. Here, we pres-
ent evidence that confirms the identity of these short bands as
WNK4 short variants that lack a portion of the C-terminal
domain. In addition, the characterization of these short variants
of WNK4 has led us to the identification of a bona fide PP1-
binding site located at the final portion ofWNK4’s C terminus,
which regulates WNK4 phosphorylation levels and, thus,
kinase activity.
Results
WNK4 short variants lacking a segment of the C-terminal
domain are observed inmouse kidney lysates
Mouse kidney lysates from WNK4/ and WNK4/ mice
were analyzed by Western blotting using antibodies directed
against three distinctWNK4 epitopes. Using two different anti-
bodies directed against N-terminal epitopes, we observed, in
addition to the band corresponding to the full-length protein, at
least two smaller bands that were absent in the WNK4/
mouse samples (Fig. 1A and Fig. S1A). These smaller bands
were more abundant in samples from TgWNK4PHAII mice (4)
(Fig. S1B) and were not detected when an antibody directed
against a C-terminal WNK4 epitope was used (Fig. 1B). These
results suggest that the small bands observed correspond to
shorter variants of WNK4, with an intact N-terminal domain
and probably lacking a segment of the C terminus. These
shorter WNK4 variants appear to be kidney-specific, as they
were not observed in lysates from testis, brain, and lung when
analyzed with a WNK4 N-terminal antibody (Fig. 1C).
Full-length WNK4 and the shorter variants were immuno-
precipitated from mouse kidney lysates and separated by SDS-
PAGE (Fig. 1D). Bands were excised from gel and individually
analyzed by MS (LC-MS/MS). For the excised gel sample con-
taining the full-length protein, tryptic peptides generated from
the whole length of the protein were detected, including pep-
tides from the C-terminal region (Fig. 1E and Table S1). In
contrast, for the gel sample containing the smallerWNK4 vari-
ants, only peptides generated from the N-terminal and middle
region of the protein were observed, whereas no peptides from
the last portion of the C-terminal domain were detected (Fig.
1E and Table S2). This confirms the identity of the small-sized
bands observed in Western blots as smaller variants of WNK4
lacking a portion of the C terminus. In addition, given that the
781–787 peptide was observed in the sample corresponding to
the shortWNK4 variants (Table S2), at least the segment com-
prising amino acid residues 1–787 must be present in the lon-
gest of the short variants. It should be noted that the large tryp-
tic peptide comprising residues 788–970 was not expected to
be detected in these assays due to its large size, and thus, the
absence of detection of this peptide may not have been due to
absence of this segment in the short WNK4 variants.
C-terminally truncatedWNK4 constructs aremore active than
full-lengthWNK4, as long as they contain the C-terminal
SPAK-binding site
To understand the impact that C-terminal truncations may
have on WNK4 activity, we generated several WNK4 mutant
constructs in which STOP codons were inserted at strategic
positions between functional motifs (Fig. 2A). This allowed us
to test the impact of the additive elimination of these motifs.
The activity of these constructs was tested in HEK293 cells
that were cotransfected with SPAK. SPAK phosphorylation
(pSPAK; Ser-373) was measured as an indicator of WNK4
activity. Almost all mutant constructs presented a higher level
of activity than WNK4-WT (Fig. 2, B and C), which was com-
parable with the activity of the WNK4-L319F mutant that
is considered to be a constitutively active mutant due to
Kidney-specific WNK4 short variants and regulation by PP1
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impaired chloride binding in the kinase domain (14). This effect
depended onWNK4 catalytic activity, because it was prevented
by introduction of the D318A mutation, which renders the
kinase catalytically inactive (Fig. 2F and Fig. S2A) (25). The only
mutant construct that did not present higher activity levels than
WNK4-WTwasWNK4-R996X. Because this mutant is only 35
amino acid residues shorter than the WNK4-T1029X mutant,
and the only functional motif known in this segment is the
SPAK-binding site comprising residues 996–999 (RFXVmotif)
(26), we deduced that the lower pSPAK levels observed with
this mutant were due to the loss of this motif. We also assessed
T-loop phosphorylation of the truncated mutants WNK4-
K1211X and -T1029X as an alternative indicator of activation
level. For both mutants, we observed higher T-loop phosphor-
ylation levels than for WNK4-WT (Fig. 2, D and E). Finally, a
representativeWNK4-truncatedmutant was tested for its abil-
ity to promote NCC activation in Xenopus laevis oocytes. In
accordance with the results obtained in HEK293 cells, the
Figure 1. Identification ofWNK4 short variants present in kidney lysates. A, Western blotting of kidney lysates of WNK4/ andWNK4/mice using an
antibody that recognizes an N-terminal epitope of WNK4 (residues 2–167 of mouse WNK4) (WNK4 antibody A described under “Experimental procedures”)
(41). In addition to the band corresponding to the full-length WNK4 (indicated by a black arrow), this antibody detects at least two additional bands that are
absent in theWNK4/ samples (white arrows). This imagehasbeenpreviouslyusedbyYang et al. (41), aspart of theWNK4antibodycharacterization; however,
noemphasiswasmadeat this time in theWNK4 short variants.B, sameas inA, but anantibody that recognizes aC-terminal epitopeofWNK4wasused (residues
1221–1243 of humanWNK4) (antibody B) (8). Only the full-lengthWNK4 is observed. Thus, the smaller bands observed inAmight correspond to shorterWNK4
variants lacking a segment of the C-terminal region. C, Western blots performedwith samples of different tissues fromWNK4/ andWNK4/mice using the
same antibody as in A. The additional bands corresponding to putative WNK4 short variants are only observed in kidney lysates. Different exposure times are
presented for clarity: 30 s for kidney and testis, 10 min for brain and lung. D, WNK4 was immunoprecipitated from kidney lysates and subjected to SDS-PAGE.
A gel fragment containing the full-length band and another one containing the smaller bands were excised as indicated, and the extracted tryptic peptides
were analyzed by LC-MS/MS. E, schematic representation of the peptides observed in LC-MS/MS assays. For the full-length band, peptides from every domain
ofWNK4were observed. For the short bands,WNK4 peptides were observed, but none of them corresponded to the C-terminal region (see also Tables S1 and
S2). This confirms that the smaller bands correspond to short WNK4 fragments that lack a portion of the C-terminal region. IP, immunoprecipitation.
Kidney-specific WNK4 short variants and regulation by PP1
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WNK4-T1029Xmutant promotedNCCactivation, whereas no
NCC activation was observed with the WNK4-WT under the
experimental conditions tested (Fig. S2B).
Elimination of a PP1-binding site located at the final portion
of the C-terminal domain increased activity of the truncated
WNK4mutants
We noted that the only common feature between the four
truncated mutants that presented higher activity levels than
WNK4-WT was the absence of the last 12 amino acid residues
of the protein. Within this region, a motif presenting the con-
sensus sequence for interaction with PP1 is present (KXVXF)
(27). Lin et al. (21) have shown that when this site and a second
putative PP1-binding site (located at positions 695–699) are
mutated, the WNK4–PP1 interaction is lost. In our hands,
however, the WNK4–PP1 interaction was preserved in a
WNK4 mutant lacking both putative PP1-binding sites (here
termed PP1a and PP1b) (Fig. 3A). However, when only a frag-
ment of WNK4’s C terminus was expressed (residues 770–
1222), which contains only the PP1b site, the absence of this site
disrupted the interactionwith PP1. This result suggests that the
PP1b site is indeed aPP1-binding site but that, in addition to the
PP1a and PP1b sites, additional motifs present in WNK4 may
be involved in the interaction.
We hypothesized that the gain of function observed in the
truncated WNK4 mutants was due to the loss of the PP1b site.
We thus tested whether elimination of the PP1a, PP1b, or both
sites could replicate the gain of function observed with the
truncated mutants. Interestingly, we observed that only the
individual elimination of the PP1b site replicated the gain-of-
function effect (Fig. 3, B andC) and that when the PP1a site was
mutated in addition to the PP1b site, the gain-of-function effect
was lost.
We next tested the effect of the cotransfection of the differ-
ent PP1 isoforms (PP1, PP1, and PP1) on the phosphoryla-
tion levels ofWNK4-WT at previously described phosphoryla-
tion sites (RRXS sites) (16). We observed that coexpression of
PP1 and PP1 promotedWNK4 dephosphorylation, whereas
coexpression of PP1 had no effect (Fig. 3D). The inability of
PP1 to dephosphorylate WNK4 may be because it binds to
Figure 2. Effect of C-terminal deletions onWNK4 kinase activity. A, schematic representation ofWNK4 protein depicting its important domains andmotifs.
The position of insertion of STOP codons for the generation of the truncated mutants is indicated. RRxS, sites of phosphorylation by protein kinase C/protein
kinase A (16); RFXV, motifs presenting consensus sequence for SPAK interaction (22); PF2-like, domain similar to the PF2 domain present in SPAK/OSR1 that in
SPAK/OSR1 forms the binding pocket for the RFXVmotif present inWNKs and Slc12 cotransporters (20, 47);Acidic domain, motif thatmediates interactionwith
the KLHL3–CUL3–RING complex (6) (PHAII-causing mutations found in WNK4 lie within this motif); PP1a/PP1b, putative protein phosphatase 1–binding sites
(21); HQ motif, motif implicated in WNK homo- and heterodimerization (23). B, representative Western blots of lysates from HEK293 cells transfected with
SPAK-HA anddifferentWNK4mutants to assess their effect on SPAKphosphorylation.C, densitometric analysis of blots presented inA shows that C-terminally
truncated WNK4 constructs have increased activity compared with full-length WNK4, and similar to that of the chloride-insensitive, constitutively active
mutant (L319F), unless the SPAK-binding site is absent. Data are mean  S.E. (error bars); *, p  0.05 versus WNK4-WT, n  4 in at least three independent
experiments. D, HEK293 cells were transfected with WNK4-WT or the indicated truncatedmutants. WNK4 was immunoprecipitated, and T-loop phosphoryla-
tion (Ser-332) was assessed by Western blotting. E, densitometric analysis shows that the baseline T-loop phosphorylation of the truncated mutants WNK4-
K1211X and -T1029X is higher than that of WNK4-WT. *, p  0.05 versus WNK4-WT, n  4 in at least three independent experiments. F, HEK293 cells were
transfected with WNK4 truncated mutants that were made catalytically inactive by introduction of the D318A mutation. These mutants were unable to
phosphorylate SPAK, showing that the higher pSPAK levels observed in the presence of catalytically active truncatedmutants are due to higher WNK4 kinase
activity.
Kidney-specific WNK4 short variants and regulation by PP1
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WNK4 with lower affinity than the other isoforms (Fig. 3E).
The effect of PP1 co-expression on WNK4 phosphorylation
levels depended on PP1 catalytic activity (Fig. S3).
Finally, we tested the effect of PP1 cotransfection on the
phosphorylation levels of the PP1 binding mutants. We
observed that the presence of the PP1b mutation (either alone
or together with the PP1a mutation) prevented the PP1-me-
diated dephosphorylation of WNK4 (Fig. 3, F and G), whereas
the WNK4–PP1a mutant behaved similarly to the WT.
Altogether, these results suggest that PP1 and PP1 are
important regulators ofWNK4 phosphorylation levels and that
they require the presence of the C-terminal binding site, here
described as PP1b, to achieve dephosphorylation. Impaired
dephosphorylation ofWNK4 in the presence of the PP1bmuta-
tion leads to kinase activation. This activation is lost in the
presence of the PP1a mutation despite high WNK4 phosphor-
ylation levels observed in this double mutant, suggesting that
the PP1a mutation impairs the kinase activity of WNK4. Of
note, the PP1a site lies within a region of WNK4 that has been
described to have a PF2-like fold similar to the one present in
SPAK and OSR1. This PF2-like domain present in SPAK and
OSR1 has been implicated in the binding of RFXVmotifs pres-
ent inWNKkinases and SLC12 cotransporters (26), and thus, it
may play a role in a key functional WNK4 interaction.
At least one of the shortWNK4 variants observed in kidney
lysatesmay be the product of a proteolytic event
The presence of two different kidney-specific short variants
of the SPAK kinase has been described. McCormick et al. (28)
reported the existence of an alternative transcript of SPAK that
was identified through a 5-RACE assay. Markadieu et al. (29)
showed that a proteolytic activity present in kidney lysates pro-
duces a cleavage in SPAK that generates SPAK fragments trun-
cated at the N terminus similar to those observed in kidney
lysates. Interestingly, it was recently shown that kidney lysates
of mice that express SPAK only in the DCT, from a transgene
carrying SPAK’s ORF, display the same pattern of bands in
SPAK blots compared with those observed with lysates of WT
mice. This suggests that the shorter variants of SPAK are pri-
marily produced by proteolytic cleavage and are present in the
DCT (3).
To investigate the origin of the short variants of WNK4
observed in kidney samples, we performed 3-RACE assays
designed to detect alternative transcripts that would produce
WNK4 proteins lacking a portion of the C terminus (Table S3)
(30). Only the previously described full-length transcript of
WNK4 was successfully amplified by this method. In addition,
we searched for alternative WNK4 transcripts in published
Figure 3. A PP1-binding site located in the C terminus of WNK4 regulates its phosphorylation and activity. A, co-immunoprecipitation assay of WNK4
and PP1. HEK293 cells were transfectedwith PP1 and either full-lengthWNK4 (left) or a C-terminal fragment ofWNK4 (residues 770–1222) (right). The effect
of elimination of the predicted PP1-binding sites was assessed. A shift in the electrophoretic mobility of the WNK4–PP1ab mutant is observed (migrates
slower). This is evenmore evident with the C-terminal fragment harboring the PP1bmutation. Such a shift may be related to the phosphorylation levels of the
protein, given that, as shown in the following panels, elimination of the PP1b site preventsWNK4 dephosphorylation. B, Western blots of lysates fromHEK293
cells transfected withWNK4 constructs in which the putative PP1-binding sites weremutated (21). Their effect on pSPAKwas assessed. PP1amutant contains
mutations V697A/T698A/F699A, and PP1b contains V1213A/T1214A/F1215A. PP1b mutant is more active than WT. C, results of quantitation of blots repre-
sented in B. Data aremean S.E. (error bars). *, p 0.05 versusWNK4-WT, n 3.D, HEK293 cells were cotransfectedwithWNK4-WT anddifferent PP1 isoforms.
Before Western blots were performed, WNK4 was immunoprecipitated from cell lysates to eliminate signal detected from other proteins with the RRXpS
antibody. Only PP1 and PP1 promoted WNK4 dephosphorylation at RRXS sites. E, WNK4 interaction with the different PP1 isoforms was assessed by
co-immunoprecipitation. Similar results were observed in three independent experiments. F, cells were cotransfected with PP1 and the indicated WNK4
mutants. WNK4was immunoprecipitated, and blots were performedwith the indicated antibodies. PP1 promotes dephosphorylation ofWNK4 at RRXS sites
(41) unless the PP1b site ismutated.G, results of quantitationof blots presented in F: phosphorylation levels ofWNK4 in thepresenceof PP1. Data aremean
S.E.; *, p 0.05 versusWNK4-WT, n 4. IP, immunoprecipitation.
Kidney-specific WNK4 short variants and regulation by PP1
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databases from mouse kidney RNA-Seq studies (GEO acces-
sion numbers GSE79443 (31) and GSE81055). Only one alter-
native transcript was found that lacks exons 14 and 15 (Fig. S4).
This transcript, however, could not explain the shortWNK4 vari-
ants that we observe in kidney lysates, because it would produce a
protein containing a portion of the C-terminal domain that is
absent in the short variants that we detect (Fig. 1).
We hypothesized that the short WNK4 variants could be
produced by proteolytic events. Full-length WNK4 carrying a
FLAG and HA epitopes at the N and C termini, respectively,
was produced in HEK293 cells. Following immunopurification,
FLAG-WNK4-HAwas incubated with 70g of kidney lysate at
37 °C for 1.5 h. Incubation with kidney lysate reduced the
amount of full-lengthWNK4 detected with the FLAG antibody
and produced a smaller band that ran between the 95 and 130
kDa markers (Fig. 4A). When probed with the HA antibody, a
smaller band of approximately 70 kDa was also observed in the
presence of kidney lysate (Fig. 4A). These small bands may cor-
respond to the N-terminal and C-terminal proteolytic frag-
ments, respectively. They were not detected in the lysate sam-
ples in the absence of FLAG-WNK4-HA (Fig. 4A), ruling them
out as nonspecific bands recognized in the kidney lysate by
these antibodies. As control, a SPAK proteolytic assay was per-
formed in parallel using immunopurified SPAK-FLAG (C-ter-
minal tag), and the previously reported proteolytic event was
clearly observed (29).
Figure 4. At least one of the short WNK4 variants observed in kidney lysates may be produced by a proteolytic event. A, FLAG-WNK4-HA (N- and
C-terminal tags) and SPAK-FLAG (C-terminal tag) were immunopurified from HEK293 lysates and incubated with kidney lysates (70 mg) at 37 °C for 1.5 h.
Western blots were performed with FLAG and HA antibodies as indicated. In the samples treated with kidney lysate, a decrease in the amount of full-length
WNK4andSPAKwasobserved, anda lower-sizedbandbecameapparent (white arrow), presumably due to aproteolytic cleavageevent. ForWNK4, lower-sized
bandswereobservedwithbothFLAGandHAantibodies, suggesting that thesebandsmaycorrespond to theN-terminal andC-terminal proteolytic fragments,
respectively. This observation was reproducible inmore than 10 independent experiments, some of which are presented in the following panels and in Fig. 5.
B, proteolytic assays were performed as described in A in the presence of different protease inhibitors: phenylmethylsulfonyl fluoride (1 mM), pepstatin A (10
M), EDTA (1mM), and1,10-phenanthroline (5mM). Theproteolytic eventwasonlyobserved in theabsenceof 1,10-phenanthroline (indicatedbyawhite arrow),
suggesting that theprotease responsible of this cleavage is Zn2-dependent. The sameobservationwasmade in two independent experiments.C, proteolytic
assays performed as described in Awith lysates of different tissues. WNK4 cleavage is more prominent using kidney lysate (indicated by a white arrow). Four
independent assays were performed with similar results. D, incubation of kidney lysates at room temperature promotes an increase in the abundance of the
shortest WNK4 fragment (white arrow). This is prevented by the addition of 1,10-phenanthroline (5 mM). Other forms of WNK4 are indicated by black and gray
arrows. Three independent assays were performed with similar results. WNK4 antibody A was used. E, a kidney lysate was prepared by immediate homogeni-
zation of frozen tissue in lysis buffer containing 1% SDS, which prevents all enzymatic activity. The short WNK4 variants were detected (white arrows),
suggesting that they are not artificially produced during tissue lysis. WNK4 antibody A was used.
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To assess which type of protease is responsible for the cleav-
age, FLAG-WNK4-HA proteolytic assays were carried out in
the presence of multiple combinations of protease inhibitors.
The proteolytic event was only observed in the reaction lacking
EDTA and 1,10-phenanthroline (Fig. 4B) and was not observed
in the reaction containing EDTA and 1,10-phenanthroline in
which Ca2 was added in a concentration that exceeds the
chelating capacity of EDTA (32). Moreover, previous reactions
in which WNK4 cleavage was observed were carried out in the
presence of the protease inhibitor mixture Complete (Roche
Applied Science), which contains EDTA at low concentrations
that are sufficient to chelate Ca2 but not Zn2 ions due to the
lower affinity against the latter. These observations suggest
that, similar to what was reported for SPAK (29), the protease
responsible for the cleavage of WNK4 is probably a Zn2-de-
pendent metalloprotease.
When lysates from different tissues were tested, the 1,10-
phenanthroline–sensitive cleavage of WNK4 was noticeably
more prominent upon incubation with kidney lysate than with
other lysates (Fig. 4C). This is consistent with the expression
pattern of the WNK4 short variants reported in Fig. 1C.
We then tested whether the proteolytic activity could be
observed in endogenous WNK4 of mouse kidney lysates.
Lysates were freshly prepared, and, immediately after homoge-
nization, the lysate was split in two, and 1,10-phananthroline
was added to one of the tubes. Aliquots were then prepared
from each tube that were incubated at 25 °C for the indicated
amounts of time (Fig. 4D). In the absence of 1,10-phenanthro-
line, a decrease in the full-length band was observed after only
1 h of incubation, and, at this time point, the abundance of the
band of lowest size already increasedwith respect to time 0 (Fig.
4D). This increase was not observed in the lysates treated with
1,10-phenanthroline, suggesting that the band of lowest size
was generated by a proteolytic cleavagemediated by aZn2-de-
pendent protease. Generalized protein degradation was also
observed, which explains the absence of band detection in the
final time points.
Finally, given the observations just mentioned, we wanted to
rule out the possibility that the shortWNK4 bands observed in
blots were produced as an artifact during lysate preparation,
because this would mean that the short variants of WNK4 do
not really exist within intact renal cells. To do this, a kidney
lysate was prepared by immediate homogenization of frozen
tissue in lysis buffer containing 1% SDS (33). This lysis method
prevents all enzymatic activity. The shortWNK4 variants were
detected in this lysate (Fig. 4E), suggesting that they are not
artificially produced during tissue lysis when WNK4 proteins
come in contact with extracellular proteases or other proteases
present in cell types that lack WNK4 expression.
RenalWNK4 short variants probably lack a SPAK-binding site
andmay be unable to phosphorylate SPAK
WNK4 in vitro proteolytic reactions were run in parallel to
kidney lysates from WNK4/ and WNK4/ mice to com-
pare the electrophoretic mobility of the WNK4 N-terminal
fragment produced in proteolytic assays with that of the short
WNK4 variants observed in lysates. Proteolytic reactions were
performed using kidney lysates from WNK4/ mice. This
allowed us to use an antibody directed against a WNK4 N-ter-
minal epitope to detect the proteolytic fragments without
detecting any WNK4 signal from the lysates used for the pro-
teolytic reaction.We observed that theWNK4N-terminal pro-
teolytic fragment runs at a height similar to that of the shortest
WNK4 variant observed in WNK4/ kidney lysates (Fig. 5A).
We then compared the electrophoreticmobility of the different
variants of WNK4 observed in kidney lysates with that of sev-
eralWNK4mutant constructs truncated at theC terminus. The
full-length WNK4 expressed in HEK293 cells presented an
electrophoretic mobility similar to that of the full-length
WNK4 observed in kidney lysates (Fig. 5B). The next WNK4
band observed in kidney lysates (the middle band) ran at a sim-
ilar height as the WNK4-L866X mutant, and the shortest
WNK4 kidney band ran faster than the WNK4-L866X mutant
and slower than the WNK4-V740X mutant. Thus, assuming
that the mobility of the renal WNK4 variants is not affected by
an unknown modification or factor that is absent in HEK293
cells, or vice versa, we can conclude that the short renalWNK4
variants probably lack the C-terminal SPAK-binding motif
(residues 996–999). According to the results presented in Fig.
2B, this would render them unable to phosphorylate SPAK.
Finally, with the purpose of narrowing down the segment of
the protein containing the site in which WNK4 is cleaved in
vitro, and probably in vivo, we generated new WNK4 mutants
harboring deletions of different portions of the C terminus (Fig.
5C). We hypothesized that the in vitro cleavage would not
be observed with the mutant lacking the cleavage site. As
expected, all but one of the five deletion mutants were cleaved
in in vitro proteolytic reactions, and cleavage was prevented by
the addition of 1,10-phenanthroline (Fig. 5D). We failed to
observe cleavage of the WNK4-740–781 mutant, suggesting
that the cleavage site may be present within the segment
flanked by residues 740–781. Consistent with this conclusion,
all three mutants harboring deletions of segments located
downstream of the putative cleavage region producedN-termi-
nal proteolytic fragments of a similar size to the one observed
with the WNK4-WT. In contrast, the WNK4-601–739
mutant produced an N-terminal proteolytic fragment of
smaller size, presumably because in this mutant, the cleavage
site is located downstream of the deletion, and thus the 601–
739 region is normally located within the N-terminal proteo-
lytic fragment.
Abundance of shortWNK4 variants is not altered by changes
in dietary Na and K content
Given that modifications in the dietary content of Na and
K affect the activity of NCC and other targets of regulation of
WNK4 (like ROMK and ENaC), we decided to test whether
these dietary modifications could also affect the abundance of
WNK4 isoforms, rationalizing that this could have an impact
on the activity of the downstream targets. No changes were
observed with the low-Na diet, and an increase in the abun-
dance of all isoforms was observed in mice given a low-K
diet (Fig. 6, A and B). The latter result is consistent with a
previous report (34), and the changes observed are probably
due to a decrease in KLHL3–CUL3-RING–mediated WNK4
degradation. However, no changes in the relative abundance
Kidney-specific WNK4 short variants and regulation by PP1
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of WNK4 forms were observed, suggesting that the cleavage
of WNK4 is not regulated in response to these dietary
manipulations.
Finally, given that it is clear that WNK4 plays an important
role inDCTphysiology, we decided to analyze the expression of
theWNK4 short variants in samples fromDCT tubules isolated
by COPASTM. Indeed, we were able to observe at least one of
the short variants in these samples. Due to the low signal
detected, it was unclear whether the second short variant is
expressed in DCT cells.
Discussion
Kidney-specific isoforms of the kinases WNK1 and SPAK
have been described. These isoforms present functional prop-
erties that differ from those of the full-length proteins (28, 35).
Hence, their characterization has been important to under-
stand the molecular pathways implicated in the regulation
of renal salt transport. Similarly, the characterization of the
WNK4 short variants described in this work may be important
to gain a more accurate understanding of WNK4’s role in kid-
ney physiology.
Figure 5. Size analysis ofWNK4 short variants.A, Western blotting ofWNK4/ andWNK4/ kidney lysates run in parallel withWNK4proteolytic reactions
(performed as in Fig. 4A, but using kidney lysates fromWNK4/mice) to compare the electrophoretic mobility of theWNK4 fragments with that of the short
band that is product of the in vitro proteolytic cleavage (white arrow). For clarity, the blot image was split in two to present two different film exposure times.
Three independent experimentswereperformed.WNK4antibodyAwasused.B,WesternblottingofWNK4/andWNK4/ kidney lysates run inparallelwith
lysates of HEK293 cells transfected with different truncatedWNK4mutants. WNK4 antibody Awas used. The electrophoretic mobility of the renal WNK4 short
variants (white arrows) suggests that theymay be around 740–866 amino acids long andmight lack a SPAK-binding site. C, schematic representation ofWNK4
constructs in which different segments were deleted to narrow down the region containing the cleavage site in WNK4. D, proteolytic assays performed with
differentWNK4 constructs harboring deletions in the C-terminal region. All constructs were cleaved upon incubationwith kidney lysate (proteolytic fragment
indicated by thewhite arrow), except for the one that lacks residues 740–782. This suggests that the cleavage sitemight be locatedwithin this segment of the
protein. Four independent experiments were performed.
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Here, we used multiple antibodies for Western blotting
assays and LC-MS/MS studies, which helped us to confirm that
indeed short fragments of WNK4 are present in kidney lysates
that lack a portion of theC-terminal domain (Fig. 1 and Fig. S1).
Given that alternative WNK4 transcripts that could explain
the shortWNK4 variants were not observed, we tested the pos-
sibility that they could be the product of a proteolytic event.
Indeed, we observed that kidney lysates appear to possess pro-
teolytic activity towardWNK4 and that this activity produces a
band of a size similar to that of the shortest WNK4 variant
observed in vivo (Figs. 4 and 5). This phenomenon was similar
to the one characterized by Markadieu et al. (29) for the kinase
SPAK: a proteolytic event giving rise to SPAK short variants
that is observed upon incubationwith kidney lysates, whichwas
prevented by the addition of 1,10-phenanthroline, an inhibitor
of Zn2metalloproteases (36). It remains unclear which is the
protease responsible for the SPAK cleavage (37).
It should be noted that only one short WNK4 fragment was
produced upon incubation of recombinantWNK4 with kidney
lysates. Thus, the origin of only one of the two short WNK4
bands observed in kidney lysates may be explained by a proteo-
lytic event. The second band may be the product of an alterna-
tive transcript that we failed to identify or the product of a
proteolytic event that was not observed in the conditions
tested.
Our experiments narrowed down the location of the cleavage
site to a 41-residue-long segment of the protein (within resi-
dues 740–781) (Fig. 5). Cleavage in this regionwould produce a
WNK4 fragment that would lack theC-terminal SPAK-binding
site (26) and theHQmotif that is important forWNKhomo- or
heterodimerization (23, 24). The same would be true for the
second short variant of larger size observed in kidney, based on
its electrophoretic mobility. Thus, these short variants may be
unable to autophosphorylate and to phosphorylate SPAK, so
one possibility is that their generation may be a mechanism to
inactivate the pathway.Another possibility is that theymay play
a role in the kinase activity-independent regulation of targets
like ENaC and ROMK (11, 12), or in the SPAK-independent
regulation of Slc12 cotransporters (26). Because no shift in the
abundance of WNK4 forms was observed in mice exposed to
low-Na or low-K diets, it is not yet clearwhether this process
is regulated. Further research will be necessary to understand
the physiological significance of the WNK4 short variants.
Interestingly, it has been recently reported that Zn2 deficiency
in DCT cells and in mice is associated with an increase in NCC
expression and activity (38). Although the mechanism is cur-
rently unknown, one possibility is that Zn2 depletion in DCT
cells may lead to decreased WNK4 and SPAK cleavage and,
thus, NCC activation.
Finally, it has been recognized that the PP1 phosphatase is an
important regulator of the WNK-SPAK/OSR1-Slc12 pathway.
For instance, it was shown that inhibition of PP1 activity by
calyculin A prevents the activation of KCCs that is observed in
the presence of kinase-inactive WNK3 (39) and inhibits the
Figure 6. Effect of changes in dietary electrolyte intake on the abundance of renalWNK4 forms. A, WT C57Bl/6mice were given normal Na diet (n 6)
or low Na diet (n 7) for a period of 4 days. Kidney lysates were prepared and WNK4 Western blots were performed with an antibody directed against an
N-terminal epitope (antibody A) (41). The full-length form is indicatedwith a black arrow. ShortWNK4 variants are indicatedwithwhite arrows. n.s., nonspecific
bands. Results of quantitation of band intensities for the full-length and short forms of WNK4 are presented. Data are mean S.E. (error bars). B, same as in A,
but mice were fed with normal or low-K diets for 7 days (n 6 for each group). Results of quantitation of band intensities for the full-length and short forms
of WNK4 are presented. Data aremean S.E. *, p 0.01 versus normal K. No apparent shift in the relative abundance of WNK4 forms was observed with any
of these dietary manipulations. C, DCTs were enriched by COPAS (43) and then subjected to Western blot analysis. At least one of the short WNK4 fragments
was observed. NCC blot was performed to confirm DCT enrichment.
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activity of KCC4 observed in hypotonic conditions (40). Later,
Lin et al. described two motifs within WNK4 that harbor the
consensus sequence required for interactionwith PP1, and they
showed that elimination of these motifs prevents WNK4–PP1
co-immunoprecipitation (21). More recently, Frenette-Cotton
et al. (40) showed thatmutation of both of thesemotifs prevents
WNK4’s ability to inhibit KCC4, and, thus, they proposed that
WNK4 inhibits PP1 activity, which translates into KCC4
down-regulation.
In the present work, the study of the short variants ofWNK4
has led us to a more comprehensive characterization of the
putative PP1-binding sites in WNK4. By directly analyzing the
ability of the WNK4–PP1 binding mutants to phosphorylate
SPAK and their phosphorylation levels in the presence of PP1,
we have obtained robust results showing that PP1 and PP1
are strong regulators of WNK4 activity by promoting WNK4
dephosphorylation (Fig. 3). We also observed that only the sec-
ond KXVXF motif present in WNK4 (here termed PP1b) is
necessary for PP1-mediated regulation of WNK4. Elimination
of this site turned WNK4 into a constitutively active kinase,
suggesting thatWNK4 activity depends on the balance between
phosphorylating stimuli (e.g. low intracellular chloride (14) or
increased angiotensin II (16)) and dephosphorylating stimuli
through PP1 and PP1. Of note, these results fit well with our
previous description of a “negative signal regulatory domain” in
WNK4 that comprises the terminal 50 residues of the protein
(18).
Regarding the first KXVXFmotif (PP1a), we show that it may
not function as a PP1-binding site, because elimination of this
site does not alter PP1-mediated WNK4 dephosphorylation.
Instead,mutation of this site ablatesWNK4 activity, even in the
context of the high levels of WNK4 phosphorylation observed
when both sites aremutated together (Fig. 3). Thus, we hypoth-
esize that this loss of activity is due to disruption of a domain
that is functionally important. Indeed, the PP1a site lies within
a region of WNK4 that has been predicted to have a PF2-like
fold similar to the one present in SPAK and OSR1. In these
kinases, the PF2 domain constitutes the binding site for RFXV
motifs present in WNK kinases and Slc12 transporters. Thus,
although we cannot yet ascribe a particular role for this domain
in WNK4, we can argue that the PP1a motif probably does not
constitute a PP1-binding site. From this perspective, the results
of Frenette-Cotton et al. (40) acquire a different interpretation;
WNK4 is not a regulator of PP1, but instead, PP1 regulates
WNK4 activity, and the observation that the WNK4 mutant
with both putative PP1-binding sites eliminated is unable to
inhibit KCC4may be explained by the fact that this is a mutant
that is unable to phosphorylate SPAK.
In conclusion, we have identified C-terminally truncated,
kidney-specific, short variants of the kinaseWNK4.At least one
of these short variants appears to be a product of a proteolytic
event, and our experiments suggest that they both probably lack
a SPAK-binding site and an HQmotif. Thus, they are probably
inactive, and their physiological relevance remains to be deter-
mined. Finally, this work has led us to the identification of a
bona fide PP1-binding site in WNK4, which is located within
the last 12 amino acid residues of the kinase. We have shown
that PP1 regulates WNK4 phosphorylation levels and, thus,
WNK4 activity.
Experimental procedures
Mouse studies
Animal studies were approved by the animal care and use
committees of our institutions.Most studies were performed in
male WT C57BL/6 mice (age 12–16 weeks). WNK4-knockout
mice and WNK4-PHAII transgenic mice were also used
(C57BL/6 background) (4, 8). Teklad custom normal diet (con-
taining 0.49% NaCl; TD.96208) and NaCl-deficient diet
(TD.90228) were given for 4 days (8). Low-K (0% K) diet was
obtained from TestDiet (St. Louis, MO), whereas normal K
was prepared by adding KCl to make a 1.2% K diet. Mice were
given these modified diets for 7 days before being sacrificed.
Western blots
Tissueswere snap-frozen in liquid nitrogen and later homog-
enized (250 mM sucrose, 10 mM triethanolamine, 1	 protease
inhibitors (Roche Applied Science), 1	 phosphatase inhibitors
(Sigma)). Protein concentration was determined by the BCA
protein assay (Pierce). Protein extracts were subjected to SDS-
PAGEand transferred to polyvinylidene difluoridemembranes.
Membranes were blocked for 1 h in 10% (w/v) nonfat milk dis-
solved in TBS-Tween 20 (TBSt). Antibodies were diluted in
TBSt containing 5% (w/v) nonfat milk. Membranes were incu-
bated with primary antibodies overnight at 4 °C and with HRP-
coupled secondary antibodies at 25 °C for 1 h. Signals were
detectedwith enhanced chemiluminescence reagent. Immuno-
blots were developed using film.
The following antibodies were used: WNK4 (N-terminal
epitope, raised in rabbit, generated by Dr. David H. Ellison’s
group (41), antibody A); tubulin (Sigma, T5168, raised in
mouse); actin (Santa Cruz Biotechnology, Inc., sc-1616 HRP,
raised in goat); HA (Sigma, H6533, raised in mouse); FLAG
(Sigma, A8592, raised in mouse); pRRXS (Cell Signaling, 9624
(16), raised in rabbit); sheep-HRP (Jackson Immunoresearch);
and rabbit-HRP (Jackson Immunoresearch). Several antibodies
were obtained from the Medical Research Council phosphory-
lation unit at Dundee University (all are polyclonal antibodies
raised in sheep): WNK4 (C-terminal epitope, S064B (8), anti-
body B); WNK4 (N-terminal epitope, S121B (41), antibody C);
pSPAK-Ser-373 (S670B) (42); and NCC (S965B) (8). The spec-
ificity of all antibodies used has been previously tested.
COPAS
Isolation of DCT has been described previously (43). Briefly,
mice expressing enhanced GFP under the PV promoter were
anesthetized and perfused with ice-cold Krebs buffer. Kidney
cortex was finely minced before incubation in digestion solu-
tion (1 mg/ml collagenase type 1 and 2,000 units/ml hyaluron-
idase in Krebs buffer, pH 7.3) for 15 min at 37 °C. Tubules col-
lected fromdigestion reactionswere placed on ice and sorted by
the COPAS. Each suspension of fluorescent tubules was col-
lected in a 1.5-ml Eppendorf tube, previously coated with 0.5%
(w/v) BSA in PBS/NaOH, pH 7.4. Tubules were lysed with
Laemmli buffer.
Kidney-specific WNK4 short variants and regulation by PP1
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Mass spectrometry
Mouse kidney lysates were prepared as described above. For
WNK4 immunoprecipitation, 1 mg of lysate was incubated
with 10 g of sheep anti-WNK4 antibody (MRC Dundee
S121B) (23) and Protein A/Gmagnetic beads (Pierce) for 2 h at
4 °C. Beads were washed five times with a buffer containing
0.025 M Tris, pH 7.4, 0.15 M NaCl, 0.001 M EDTA, 1% Nonidet
P40, 5% glycerol. Bound proteins were eluted by incubation in
glycine buffer, pH 2, for 10 min and then prepared for SDS-
PAGE. Bands were excised from the gel and processed at the
MS and Proteomics Resource at Yale. Briefly, on a tilt table, the
gel band was washed with 1) 250 l of 50% acetonitrile for 5
min, followed by 2) 250l of 50% acetonitrile containing 50mM
NH4HCO3 for 10–30 min, and then finally with 3) 250 l of
50% acetonitrile containing 10 mM NH4HCO3 for 10–30 min.
The final wash was removed, and the gel was SpeedVac-dried.
60l of a 1:15 dilution of a 0.1mg/ml trypsin stock solutionwas
added to the gel and allowed to absorb for 10min. An additional
volume of 10 mM NH4HCO3 was added to cover the gel pieces
and then incubated at 37 °C for 18 h. Peptides were then
extracted by adding 250 l of 0.1% TFA, 80% acetonitrile and
shaking for 30 min. Extract was transferred to a new tube and
dried. Dried peptide pellet was dissolved in 70% formic acid,
diluted with 0.1% TFA, and finally subjected to LC-MS/MS
analysis using the LTQ Orbitrap XL that is equipped with a
Waters nanoACQUITY UPLC system and uses a Waters Sym-
metry C18 180 m 	 20-mm trap column and a 1.7 m, 75
m	 250-mmnanoACQUITYUPLC column for peptide sep-
aration. The acquired data were peak-picked and searched
using the Mascot Distiller and the Mascot search algorithm,
respectively. Protein identificationwas achieved using theMas-
cot search algorithm (Matrix Science) as described (44), and
MS spectral features were searched against the SWISSPROT
Mouse database along with a user-generated WNK4 protein
database.
Cell culture
HEK293 cells (ATCC CRL-1573) were used for transient
transfection of mWNK4-HA, FLAG-mWNK4 (16), HA-SPAK,
SPAK-FLAG (FLAG inserted in the C-terminal by FastCloning
(45)), and FLAG-PP1-, -, and - (kindly provided by Dr. Jer-
emyNichols) (46). Cells were grown to 70–80% confluence and
transfected with Lipofectamine 2000 (Life Technologies, Inc.).
Mutations were introduced into the WNK4 clone by site-di-
rectedmutagenesisusingPhusionhigh-fidelityDNApolymer-
ase (New England Biolabs) and confirmed by Sanger sequenc-
ing. Deletions were performed by FastCloning (45). 48 h after
transfection, cells were lysed with a lysis buffer containing 50
mM TrisHCl (pH 7.5), 1 mM EGTA, 1 mM EDTA, 50 mM
sodium fluoride, 5 mM sodium pyrophosphate, 1 mM sodium
orthovanadate, 1% (w/v) Nonidet P-40, 270 mM sucrose, 0.1%
(v/v) 2-mercaptoethanol, and protease inhibitors (Complete
tablets; RocheApplied Science), and protein concentrationwas
quantified.
In vitro proteolytic assays
Recombinant FLAG-mWNK4-HAwas immunoprecipitated
using a FLAG Immunoprecipitation Kit (FLAGIPT1, Sigma).
After washing the beads, 70 g of kidney lysate (prepared with
lysis buffer containing 125mMNaCl, 10%glycerol, 1mMEGTA,
1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 M leu-
peptin, 4M aprotinin, 10M pepstatin, 1% Triton X-100, 0.5%
SDS, 20 mM HEPES, pH 7.4) was added to the beads and incu-
bated for 90 min at 37 °C (final reaction volume of 30 l in 50
mM HEPES, 140 mM NaCl, pH 7.4, with protease inhibitors as
indicated). Reactions were stopped by adding Laemmli buffer
and heating at 95 °C for 10 min. Eluates were used for Western
blotting assays.
Statistical analysis
For comparison between two groups, unpaired Student’s t
test (two-tailed) was used. For comparison between multiple
groups, analysis of variance tests were performed, followed by
Tukey post hoc tests. A difference between groups was consid-
ered significant when p 0.05.
Na uptake experiments
The use of X. laevis frogs was approved by our institutional
committee on animal research. NCC activity was assessed in
X. laevis oocytes microinjected with NCC cRNA alone or
together with WT WNK4 or WNK4-T1029X. Two days post-
injection, the thiazide-sensitive Na uptake was assessed as
described previously (9). Briefly, 22Na tracer uptake was
assessed in groups of 10–15 oocytes. A 30-min incubation at
32 °C in aCl-freeND96mediumcontaining 1mMouabain, 0.1
mM amiloride, and 0.1 mM bumetanide was followed by a
60-min uptake period in a K-free NaClmedium (40mMNaCl,
56mM sodium gluconate, 4.0mMCaCl2, 1.0mMMgCl2, and 5.0
mM HEPES, pH 7.4) containing ouabain, amiloride, bumet-
anide, and 2 Ci of 22Na/ml. Oocytes were washed five times
in ice-cold uptake solution to remove tracer in the extracellular
fluid. Individual oocytes were dissolved in 10% SDS, and the
tracer activity was determined for each oocyte by -scintilla-
tion counting.
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